The U.S. military’s plan to test testosterone replacement therapy spotlights growing interest in hormone‑based performance aids and raises regulatory and market questions for the TRT industry
Executive summary: The U.S. military announced plans to test testosterone replacement therapy on troops, as reported by CNBC on July 20, 2026. The move highlights the therapy’s benefits for qualified patients and concerns about long‑term risks and off‑label use, potentially affecting defense health spending and pharmaceutical markets.
Who is involved: U.S. military personnel and health officials overseeing the testing program.
Likely next: The testing program will proceed, generating data on efficacy and safety that will be reviewed by military health authorities.
While some research has shown benefits for patients who qualify, questions remain about the therapy's long-term risks and use among men without a medical need. The U.S. military’s announcement to test troops brings these considerations into a defense‑sector context.
Timeline
- — What to know about testosterone replacement therapy as the U.S. military plans to test troops (CNBC — Business)
Analysis — what this means
Sectors affected
- Testosterone replacement therapy (pharmaceuticals)
- Defense health care services
Regulatory implications
- Data produced by the military's testosterone replacement therapy testing will be available for regulatory assessment.